New Paper: Targeting negative symptoms in schizophrenia with tDCS
Schizophr Res. 2015 Aug;166(1-3):362-3. doi: 10.1016/j.schres.2015.05.029.
Targeting negative symptoms in schizophrenia: results from a proof-of-concept trial assessing prefrontal anodic tDCS protocol.
Kurimori M, Shiozawa P, Bikson M, Aboseria M, Cordeiro Q.
“….In the present study anodic tDCS protocol was found to ameliorate negative symptoms in schizophrenia. The present results need to be taken as hypothesis-driven given the study design. Limitations to this study include its unblinded nature, small sample size, lack of a control group, and short length. Moreover, our results may be overestimated due to intrinsic characteristics such as the placebo effect and Hawthorne effect. However, the current “proof-of-concept” trial is aimed at evaluat- ing preliminary effects of a new experimental tDCS protocol. We under- stand that the trends seen in the completers shall strongly justify a larger double-blind study with better estimation of sample size.”